Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
As shown, the age of menarche (13.43 ± 1.34 vs. 12.25 ± 3.77 years), regular menstruation (85.4% vs. 75.3%), previous live births, positive aCL IgG (26.5% vs. 15.6%), PT (11.11 ± 0.96 vs. 12.56 ± 11.46 s), and levels of IgA (12.64 ± 2.51 vs. 10.22 ± 4.51 g/L), IgG (2.27 ± 0.8 vs. 3.94 ± 3.81 g/L), C3 (1.28 ± 0.22 vs. 1.39 ± 0.21 g/L), TC (4.15 ± 0.98 vs. 4.4 ± 0.95 mmol/L), HDL-C (1.22 ± 0.32 vs. 1.51 ± 0.66 mmol/L) and 25-hydroxyvitamin D levels (12.47 ± 6.13 vs. 15.95 ± 7.46 ng/mL) were significantly different between the two cohorts (all P < 0.05).Comparison of baseline and clinical characteristics of training cohort and validation cohortVariablesTraining cohort N = 302Validation cohort N = 77P valueMaternal age (years)30.89 ± 4.3131.79 ± 4.250.100BMI (kg/m2)24.43 ± 3.6724.54 ± 3.650.829Age of menarche (years)13.43 ± 1.3412.25 ± 3.77<0.001Regular menstruation258 (85.4)58 (75.3)0.033Dysmenorrhea degree0.305 Never115 (38.1)21 (27.3) Slight139 (46.0)44 (57.1) Obvious31 (10.3)8 (10.4) Serious17 (5.6)4 (5.2)Education level0.276 Primary school8 (2.6)3 (3.9) Middle school39 (12.9)16 (20.8) High school52 (17.2)8 (10.4) Undergraduate193 (63.9)48 (62.3) Postgraduate10 (3.3)2 (2.6)Previous live births0.006 0262 (86.8)57 (74.0) 137 (12.3)16 (20.8) 22 (0.7)4 (5.2) 31 (0.3)0 (0)Previous pregnancy losses0.495 1125 (41.4)34 (44.2) 2117 (38.7)29 (37.7) 339 (12.9)9 (11.7) ≥421 (7.0)5 (6.5)Type of previous pregnancy losses0.051 Primary259 (85.8)59 (76.6) Secondary43 (14.2)18 (23.4)FBG (mmol/L)5.18 ± 0.975.11 ± 1.530.6162hPG (mmol/L)7.18 ± 2.67.7 ± 3.430.141TC (mmol/L)4.15 ± 0.984.4 ± 0.950.046TG (mmol/L)1.74 ± 1.321.67 ± 0.920.698HDL-C (mmol/L)1.22 ± 0.321.51 ± 0.66<0.001LDL-C (mmol/L)2.73 ± 0.792.59 ± 0.770.167TSH (μIU/mL)2.6 ± 1.442.54 ± 1.930.796FT-3 (pmol/L)5.27 ± 1.185.73 ± 5.710.187FT-4 (pmol/L)16.24 ± 4.0516.55 ± 2.740.527TG-Ab (+)58 (19.2)16 (20.8)0.756TPO-Ab (+)61 (20.2)20 (26.0)0.270PT (s)11.11 ± 0.9612.56 ± 11.460.029APTT (s)29.84 ± 5.8831.28 ± 5.520.053TT (s)14.68 ± 2.3515.99 ± 16.490.184D-dimer (mg/L)0.3 ± 0.330.32 ± 0.270.720FDP (mg/L)0.91 ± 0.790.87 ± 0.590.704IgA (g/L)12.64 ± 2.5110.22 ± 4.51<0.001IgG (g/L)2.27 ± 0.83.94 ± 3.81<0.001IgM (g/L)1.51 ± 0.621.48 ± 0.610.689Complement 3 (g/L)1.28 ± 0.221.39 ± 0.21<0.001Complement 4 (g/L)0.34 ± 0.370.36 ± 0.10.683ANA (+)39 (12.9)16 (20.8)0.080aCL IgG (+)80 (26.5)12 (15.6)0.046aCL IgM (+)81 (26.8)16 (20.8)0.278aβ2GP1 IgG (+)78 (25.6)16 (20.8)0.360LA1/LA2 ratio1.09 ± 0.171.06 ± 0.130.158Hcy (μmol/L)12.08 ± 9.3510.12 ± 6.010.08225-hydroxyvitamin D (ng/mL)12.47 ± 6.1315.95 ± 7.46<0.001Variables are given as mean ± SD or frequency with percentages. (+) represents “positive”BMI body mass index, FBG fasting blood glucose, 2hPG 2-hours plasma glucose in the 75 g oral glucose tolerance test, TC total cholesterol, TG total glycerides, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, TSH thyroid-stimulating hormone, FT-3 free triiodothyronine, FT-4 free thyroxine, TG-Ab thyroglobulin antibody, TPO-Ab thyroid peroxidase antibody, PT prothrombin time, APTT activated partial thrombin time, TT thrombin time, FDP fibrinogen degradation products, ANA antinuclear antibody, aCL anticardiolipin antibody, aβ2GP1 anti-β2 glycoprotein 1 antibody, LA1 lupus anticoagulant (LA) screening test, LA2 LA confirmatory test, Hcy homocysteine
Source: Patients’ characteristics. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
Patients were diagnosed with abnormal glucose/lipid metabolism in accordance with the Guideline for the Prevention and Treatment of Type 2 Diabetes Mellitus in China (2020 edition) and Chinese Guidelines for Lipid Management (2023 edition).
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
A predictive model of pregnancy loss using pre-pregnancy endocrine and immunological parameters in women with abnormal glucose/lipid metabolism and previous pregnancy loss
Study design awaiting verification · Endocrine · 2024
Original publication title
A predictive model of pregnancy loss using pre-pregnancy endocrine and immunological parameters in women with abnormal glucose/lipid metabolism and previous pregnancy loss
© The Author(s) 2024
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What objectives does the paper state?
To investigate the clinical and endocrine risk factors for pregnancy loss in women with abnormal glucose/lipid metabolism and a history of pregnancy loss, and to develop a predictive model to assess the risk of pregnancy loss in these women’s subsequent pregnancies.
Source: ObjectiveAbstract: What methods does the paper describe?
Patients with a history of pregnancy loss who had abnormal glucose/lipid metabolism were retrospectively included in this study, and their pre-pregnancy baseline and clinical characteristics were collected. A predictive nomogram was constructed based on the results of the multivariable logistic regression model analysis, and its calibration and discriminatory capabilities were evaluated. The internal validation was then performed and the net benefits were assessed by the clinical decision curve.
Source: MethodsAbstract: Results
The predictive model was eventually incorporated eight variables, including maternal age, previous pregnancy losses, anticardiolipin antibody (aCL) IgG, aCL IgM, thyroid peroxidase antibody, complement 4, free thyroxine and total cholesterol. The area under the curve (AUC) of the nomogram was 0.709, and Chi-square value and P value of the Hosmer: Lemeshow test were 12.786 and 0.119, respectively, indicating that the nomogram had a satisfactory calibration and discriminatory performance. The validation cohort showed a similar result for the discrimination of the nomogram (AUC = 0.715).
The clinical decision curve demonstrated the nomogram had good positive net benefits.
Source: ResultsAbstract: Conclusions
This is the first study to predict the risks of subsequent pregnancy loss in women with abnormal glucose/lipid metabolism and history of pregnancy loss using pre-pregnancy clinical and endocrine parameters. This predictive nomogram may provide clinicians assistance to personalize the management of subsequent pregnancies in these patients.
Source: ConclusionsAuthors’ abstract
Objective
To investigate the clinical and endocrine risk factors for pregnancy loss in women with abnormal glucose/lipid metabolism and a history of pregnancy loss, and to develop a predictive model to assess the risk of pregnancy loss in these women’s subsequent pregnancies.
Methods
Patients with a history of pregnancy loss who had abnormal glucose/lipid metabolism were retrospectively included in this study, and their pre-pregnancy baseline and clinical characteristics were collected. A predictive nomogram was constructed based on the results of the multivariable logistic regression model analysis, and its calibration and discriminatory capabilities were evaluated. The internal validation was then performed and the net benefits were assessed by the clinical decision curve.
Results
The predictive model was eventually incorporated eight variables, including maternal age, previous pregnancy losses, anticardiolipin antibody (aCL) IgG, aCL IgM, thyroid peroxidase antibody, complement 4, free thyroxine and total cholesterol. The area under the curve (AUC) of the nomogram was 0.709, and Chi-square value and P value of the Hosmer: Lemeshow test were 12.786 and 0.119, respectively, indicating that the nomogram had a satisfactory calibration and discriminatory performance. The validation cohort showed a similar result for the discrimination of the nomogram (AUC = 0.715).
The clinical decision curve demonstrated the nomogram had good positive net benefits.
Conclusions
This is the first study to predict the risks of subsequent pregnancy loss in women with abnormal glucose/lipid metabolism and history of pregnancy loss using pre-pregnancy clinical and endocrine parameters. This predictive nomogram may provide clinicians assistance to personalize the management of subsequent pregnancies in these patients.
Publication and source details
Original title: A predictive model of pregnancy loss using pre-pregnancy endocrine and immunological parameters in women with abnormal glucose/lipid metabolism and previous pregnancy loss
Fangxiang Mu; Mei Wang; Xianghui Zeng; Lin Liu; Fang Wang
Endocrine · 2024
© The Author(s) 20242024https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.Science Foundation of Lanzhou University Second HospitalYJS-BD-19YJS-BD-19YJS-BD-19YJS-BD-19YJS-BD-19Science Foundation of Lanzhou University071100132071100132071100132071100132071100132Medical Innovation and Development Project of Lanzhou Universitylzuyxcx-2022-137lzuyxcx-2022-137lzuyxcx-2022-137lzuyxcx-2022-137lzuyxcx-2022-137Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T10:55:58.963051+00:00
DOI: 10.1007/s12020-024-03937-7 · PMC11445311